Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study

Dong Min Cha1, Tae Wan Kim2,3*, Jang Won Heo2, Se Joon Woo4, Kyu Hyung Park4, Hyeong Gon Yu2 and Hum Chung2

Abstract
Background: To compare the long-term efficacy of ranibizumab versus bevacizumab for myopic choroidal neovascularization (CNV).

Methods: This was a retrospective, multicenter, comparative, non-randomized study of 64 consecutive patients with myopic CNV treated with ranibizumab (22 patients) or bevacizumab (42 patients). Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography were evaluated before and after treatment. All the patients were followed for at least 12 months.

Results: BCVA (logarithm of the minimal angle of resolution) improved from 0.63 ± 0.30 to 0.43 ± 0.27, 0.41 ± 0.37, 0.40 ± 0.39, 0.39 ± 0.43, and 0.39 ± 0.42 at 1, 2, 3, 6, and 12 months after treatment in the ranibizumab group, and from 0.67 ± 0.28 to 0.52 ± 0.31, 0.49 ± 0.31, 0.47 ± 0.31, 0.42 ± 0.32, and 0.46 ± 0.43 in the bevacizumab group (all P < 0.05 compared with baseline BCVA in each group). CFT decreased by 20.21%, 19.58%, and 22.43% from the baseline 304 ± 76 μm at 3, 6, and 12 months after treatment in the former group, and by 15.20%, 15.67%, and 15.56% from the baseline 297 ± 62 μm in the latter group (all P < 0.05 compared with baseline CFT in each group). BCVA improvement and CFT reduction did not statistically differ when compared at the same periods from treatment between 2 groups. Neither ocular nor systemic safety problems appeared during follow up.

Conclusions: This study showed a similar functional and anatomical improvement after treatment of ranibizumab and bevacizumab for myopic CNV over a 12-month follow-up period.

Keywords: Anti-VEGF (vascular endothelial growth factor), Bevacizumab, Myopic choroidal neovascularization, Ranibizumab

Background
Myopic choroidal neovascularization (CNV) is the most common macular complication of pathologic myopia, with reported incidence ranging from 4–11% in highly myopic eyes [1,2]. Myopic CNV has typical characteristics including small size, more often subfoveal or juxtafoveal location, absence or minimal presence of subretinal fluid, and hemorrhage in the background of tigroid fundus appearance. Early consideration of myopic CNV is important because it often affects young people and its natural course without treatment is poor [1,2]. Various treatment protocols including direct photocoagulation, macular translocation, and photodynamic therapy (PDT) have been proposed; however these treatments for myopic CNV have not been satisfactory in the long term. In particular, PDT did not show a statistically significant treatment benefit for myopic CNV compared with a placebo group in the 2-year outcome in spite of its positive...
effect at 12 months in the Verteporfin in Photodynamic (VIP) trial [3,4].

The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the paradigm of various retinal diseases. Several reports have demonstrated the effectiveness of anti-VEGF agents including ranibizumab and bevacizumab for myopic CNV [5-13]. However, only a few studies have directly compared the effectiveness of treatment for myopic CNV between ranibizumab and bevacizumab [14-17]. Gharibiya et al. [14] reported that ranibizumab and bevacizumab had similar functional and anatomical effects on myopic CNV at 6-month follow up. Iacono et al. reported that these two drugs showed similar visual improvement over an 18-month follow-up in subfoveal CNV, although ranibizumab achieved greater efficacy than bevacizumab in terms of the mean number of injections administered [16]. Here, we compared functional and anatomical treatment effectiveness for myopic CNV between these 2 anti-VEGF agents over a 12-month follow-up period after treatment.

Methods

One hundred twenty two eyes of 110 patients who were diagnosed with myopic CNV from 2007 to 2009 at 3 tertiary medical centers (Seoul National University Hospital, SNUH; Seoul National University Bundang Hospital, SNUBH; and Seoul National University Boramae Medical Center, SNUBMC) were retrospectively chart-reviewed in 2010, and 66 eyes of 64 patients satisfying inclusion and exclusion criteria were included in the study. The study protocol was approved by the Institutional Review Boards of the 3 hospitals and adhered to the tenets of the Declaration of Helsinki.

Inclusion criteria were as follows: (1) axial length more than 26 mm or spherical equivalent less than −6.0 DspH (if patients had a history of cataract operation or refractive surgery, preoperative spherical equivalent was applied); (2) pathologic myopia classified as M2 or more according to the criteria of Avila et al. [18]; (3) myopic CNV that was newly diagnosed without prior treatment history; (4) pretreatment best-corrected visual acuity (BCVA) between 20/500 and 20/30; and (5) 12 or more months of follow up from treatment. Exclusion criteria were as follows: (1) history of treatment using photodynamic therapy or any intravitreal injection for myopic CNV before enrollment; (2) history of intraocular surgery except for cataract operation; (3) cataract operation which was performed less than 6 months before enrollment; (4) any other ocular disorder decreasing visual acuity such as corneal opacity, advanced cataract, or optic neuropathy; (5) cataract operation or Nd-YAG capsulotomy for after-cataract during the follow-up period; (6) BCVA less than 20/500 or more than 20/30; (7) follow-up period less than 12 months.

A thorough ophthalmic examination was performed in all patients. BCVA was measured using a Snellen chart and auto-refraction. Diagnosis of myopic CNV was confirmed when fluorescein angiography (FA; Topcon, Tokyo, Japan) revealed increased leakage over foveal area in the late phase compared with the early phase and the existence of neovascular lesion or subretinal fluid was observed with optical coherence tomography (OCT). The location of myopic CNV, which was classified into subfoveal, juxtafoveal, or extrafoveal one, was determined using both FA and fundus photography (Topcon, Tokyo, Japan). Three OCT modalities were used to evaluate central foveal thickness (CFT): Stratus OCT (Carl Zeiss Meditec, Dublin, CA), Cirrus OCT (Carl Zeiss Meditec, Dublin, CA), and Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany). The same OCT modality was always used in each patient to measure CFT so that the error arising from changing OCT modalities could be minimized.

After explaining the patients the pros and cons of two anti-VEGF agents sufficiently, one anti-VEGF agent between bevacizumab (Avastin; Genetech, San Francisco, California, USA) and ranibizumab (Lucentis; Genentech, San Francisco, California, USA) was selected by the patients. A volume of 0.05 mL (1.25 mg bevacizumab or 0.5 mg ranibizumab) was injected into the vitreous cavity using a 30-gauge needle after topical anesthesia was induced by 1 drop of 0.5% proparacaine hydrochloride (Alcaine, Alcon Laboratories, Fort Worth, TX, USA) and povidone-iodine was applied inside the cul-de-sac.

All the patients followed 1 + PRN (Pro Re Nata) protocol. They were followed at 4-week intervals after the first injection. At visits, BCVA, thorough ophthalmic examination, FA, and OCT were performed. When intraretinal or subretinal fluid remained on OCT or fluorescein leakage was persistent on FA, an additional intravitreal injection of anti-VEGF agent was performed to the first injection. When the lesion subsided totally, the follow-up period was lengthened from 4 weeks to 2–3 months without treatment. All the patients were followed for at least 12 months from the first visit.

The primary outcome measures were changes in BCVA from baseline to 1, 2, 3, 6, and 12 months after treatment and the decreased rate (%) of the CFT from baseline to 3, 6, and 12 months after treatment in the bevacizumab and ranibizumab groups. Snellen visual acuity was converted to the logarithm of the minimum angle of resolution (logMAR). The secondary outcome measures were as follows: (1) the proportions of patients who gained or lost 2 or more lines of Snellen visual acuity at 6 and 12 months after treatment compared with baseline BCVA, (2) the proportions of patients in whom CFT was increased or decreased by 10% or more at 6 and 12 months in comparison with baseline CFT, (3) the rates at which FA revealed leakage at the late phase at 3,
6, and 12 months after treatment, (4) recurrence rates during 12 months after treatment, and (5) any complications associated with intravitreal injection over the follow-up period.

We used independent t-test, paired t-test, Pearson’s chi-square test, Mann–Whitney test, and Wilcoxon signed rank test to analyze demographic data and outcome measures. Statistical analyses were performed using SPSS for Windows (Ver. 18.0, Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL). P values < 0.05 were considered significant.

Results

Demographic data for the ranibizumab and bevacizumab groups are summarized in Table 1. The 64 patients comprised 42 patients in SNUH, 18 patients in SNUBH, and 4 patients in SNUBMC. No statistical differences between groups were observed for age, sex, laterality, refraction, axial length, follow-up period, lens status, pretreatment logMAR BCVA, location of CNV, or CFT.

For 1 year after treatment, the total number of injections was 2.43 ± 1.04 and 2.72 ± 0.96, respectively (P = 0.27). In the ranibizumab group, logMAR BCVA improved from 0.63 ± 0.30 to 0.43 ± 0.27, 0.41 ± 0.37, 0.40 ± 0.39, 0.39 ± 0.43, and 0.39 ± 0.42 at 1, 2, 3, 6, and 12 months post-treatment, respectively, and statistically significant differences were observed between pretreatment and all post-treatment BCVA values (all P < 0.05). In the bevacizumab group, BCVA improved from 0.67 ± 0.28 to 0.52 ± 0.31, 0.49 ± 0.31, 0.47 ± 0.31, 0.42 ± 0.32, and 0.46 ± 0.43 at 1, 2, 3, 6, and 12 months post-treatment, respectively, and statistically significant differences were also observed between pretreatment and all post-treatment BCVA values (all P < 0.05). When BCVA values of the same period were compared between the 2 groups, no statistically significant differences were observed (P = 0.22, 0.36, 0.43, 0.71, and 0.52 at 1, 2, 3, 6, and 12 months post-treatment, respectively) (Figure 1).

Seventeen eyes in the ranibizumab group and 32 eyes in the bevacizumab group that underwent OCT examination at pre-treatment and 3, 6, and 12 months post-treatment were included in the analysis of CFT. Pretreatment CFT of the ranibizumab and bevacizumab groups was 304 ± 76 and 297 ± 62 µm, respectively (P = 0.72). In the ranibizumab group, CFT decreased by 20.21%, 19.58%, and 22.43% at 3, 6, and 12 months post-treatment, respectively, and statistically significant differences were observed between pretreatment and all post-treatment CFT values (all P < 0.05). In the bevacizumab group, CFT decreased by 15.20%, 15.67%, and 15.56% at 3, 6, and 12 months post-treatment, respectively, and statistically significant differences were observed between pretreatment and all post-treatment CFT values (all P < 0.05). When the rates of decreased CFT at the same period were compared between the 2 groups, no statistically significant differences were observed (P = 0.25, 0.33, and 0.15 at 3, 6, and 12 months post-treatment, respectively). When the absolute CFT values at the same period were compared, there were also no statistically significant differences between the 2 groups (P = 0.65, 0.77, and 0.41 at 3, 6, and 12 months post-treatment, respectively) (Figure 2).

The proportions of patients who gained or lost 2 or more lines of Snellen BCVA and in whom CFT decreased or increased by 10% or more at 6 and 12 months were compared between pretreatment and all post-treatment BCVA values (all P < 0.05). When BCVA values of the same period were compared between the 2 groups, no statistically significant differences were observed (P = 0.22, 0.36, 0.43, 0.71, and 0.52 at 1, 2, 3, 6, and 12 months post-treatment, respectively) (Figure 1).

Table 1 Patients demographics between ranibizumab and bevacizumab groups

| Parameters                      | Ranibizumab   | Bevacizumab  | P value* |
|---------------------------------|---------------|--------------|----------|
| Number                          | 22 patients   | 42 patients  | 0.12     |
|                                 | 23 eyes       | 43 eyes      |          |
| Age (years)                     | 50.48 ± 12.38 | 55.70 ± 12.78| 0.12     |
| Gender (male:female)            | 3:19          | 13:29        | 0.09     |
| Laterality (right:left)         | 16:7          | 24:19        | 0.28     |
| Refraction (diopter)            | −12.34 ± 5.05 | −14.85 ± 6.21| 0.32     |
| Axial length (mm)               | 30.28 ± 1.32  | 30.45 ± 1.51 | 0.87     |
| Follow-up period (month)        | 22.87 ± 9.10  | 22.44 ± 9.41 | 0.86     |
| Lens status                     |               |              | 0.76     |
| Phakia                          | 16            | 25           |          |
| Pseudophakia or aphakia         | 7             | 18           |          |
| BCVA (logMAR)                   | 0.63 ± 0.30   | 0.67 ± 0.28  | 0.59     |
| Location of CNV                 |               |              | 0.71     |
| Subfoveal                       | 15 (65%)      | 30 (70%)     |          |
| Juxtafoveal                     | 8 (33%)       | 13 (30%)     |          |
| CFT (µm)                        | 304 ± 73      | 287 ± 71     | 0.40     |

CNV choroidal neovascularization; BCVA best-corrected visual acuity; logMAR logarithm of the minimal angle of resolution; CFT central foveal thickness.

*Independent t-test or Pearson's chi-square test were used.
after treatment are summarized in Table 2. At 6 month follow up, BCVA improved by 2 or more lines in 18 of 23 eyes (78%) and 27 of 43 eyes (63%) in each group ($P = 0.24$). Only 1 eye in each group experienced loss of 2 or more lines of BCVA despite the intravitreal injections ($P = 0.99$). At 12-month follow up, BCVA improved by 2 or more lines in 17 of 23 eyes (74%) and 27 of 43 eyes (63%) in each group ($P = 0.43$) and worsened in 1 of 23 eyes and 2 of 43 eyes in the groups ($P = 0.99$). At 6-month follow up, CFT decreased by 10% or more in 13 of 17 eyes (77%) and 24 of 32 eyes (75%) in each group ($P = 0.91$) and increased by 10% or more in only 1 eye in the bevacizumab group ($P = 0.99$). At 12-month follow up, CFT decreased by 10% or more in 14 of 17 eyes (82%) and 22 of 32 eyes (69%) in each group ($P = 0.50$) and increased by 10% or more in 2 of 32 eyes (6%) in the bevacizumab group ($P = 0.54$).

FA revealed leakage at the late phase in 4 of 22 eyes in the ranibizumab group and 8 of 31 eyes in the bevacizumab group at 3-month follow up ($P = 0.74$), 1 of 22 eyes and 3 of 34 eyes at 6-month follow up ($P = 1.00$), and 1 of 19 eyes and 4 of 33 eyes at 12-month follow up ($P = 0.64$). Myopic CNV recurred in 1 of 23 eyes in the ranibizumab group and 5 of 43 eyes in the bevacizumab group during 12-month follow up ($P = 0.66$, Fisher’s exact test). The former recurred at 9 months after treatment, and an additional intravitreal ranibizumab injection was performed. The latter all recurred at 12 months after treatment, and additional bevacizumab injections were performed. No severe complications such as endophthalmitis or increased intraocular pressure occurred in either group over the follow-up period.

**Discussion**

The introduction of anti-VEGF agents such as ranibizumab and bevacizumab has made ophthalmologists consider it the first-choice treatment for various retinal disorders. Several multi-center, randomized, prospective studies have demonstrated anti-VEGF agents to be an effective treatment option for diabetic macular edema, retinal vein obstruction macular edema, and exudative choroidal neovascularization. Graph shows serial changes in best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution (logMAR)) from baseline to 12 months after treatment. There were significant improvements from baseline BCVA after treatment in both groups. No statistical differences of BCVA were observed at the same periods after treatment between two groups.

**Table 2 Ranibizumab versus bevacizumab for myopic CNV: BCVA and CFT changes at month 6 and 12 after treatment**

|                  | Ranibizumab | Bevacizumab | $P$ value* |
|------------------|-------------|-------------|------------|
| **BCVA changes at month 6** |             |             |            |
| Gained ≥ 2 Lines | 18/23 (78%) | 27/43 (63%) | 0.24       |
| Lost ≤ 2 Lines   | 1/23 (4%)   | 1/43 (2%)   | 0.99       |
| **BCVA changes at month 12** |             |             |            |
| Gained ≥ 2 Lines | 17/23 (74%) | 27/43 (63%) | 0.43       |
| Lost ≤ 2 Lines   | 1/23 (4%)   | 2/43 (5%)   | 0.99       |
| **CFT changes at month 6** |             |             |            |
| Decreased by 10% or more | 13/17 (77%) | 24/32 (75%) | 0.91       |
| Equal | 4/17 (23%) | 7/32 (22%) |
| Increased by 10% or more | 0/17 (0%) | 1/32 (3%) | 0.99       |
| **CFT changes at month 12** |             |             |            |
| Decreased by 10% or more | 14/17 (82%) | 22/32 (69%) | 0.50       |
| Equal | 3/17 (18%) | 8/32 (25%) |
| Increased by 10% or more | 0/17 (0%) | 2/32 (6%) | 0.54       |

*Pearson’s chi-square test was used.

**CNV** choroidal neovascularization; **BCVA** best-corrected visual acuity; **CFT** central foveal thickness.

---

**Figure 1** Change of BCVA after treatment of ranibizumab and bevacizumab for myopic choroidal neovascularization. Graph shows serial changes in best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution (logMAR)) from baseline to 12 months after treatment. There were significant improvements from baseline BCVA after treatment in both groups. No statistical differences of BCVA were observed at the same periods after treatment between two groups.

**Figure 2** Change of CFT after treatment of ranibizumab and bevacizumab for myopic choroidal neovascularization. Graph shows changes of central foveal thickness (CFT) in optical coherence tomography from baseline to 12 months from treatment in both groups. There were significant decreases from baseline CFT after treatment in both groups. No statistical differences of CFT were observed at the same periods after treatment between two groups.
In myopic CNV, although no large-scale, multi-center, randomized study has demonstrated the efficacy of anti-VEGF agents to date, many small scale studies have indicated that intravitreal anti-VEGF agent injection can improve functional and anatomical visual outcomes [5-13]. Recently, Ruiz-Moreno et al. reported that the improvement of visual outcomes maintained in 4 year follow-up in myopic CNV patients treated with anti-VEGF agents [17].

Both ranibizumab and bevacizumab are humanized murine monoclonal antibodies against VEGF, but there are some differences between them. The former consists of a 49-kD Fab fragment of antibody; the latter is a 149-kD whole antibody. Ranibizumab may have faster retinal penetration in comparison with bevacizumab due to its smaller molecular size, which would aid in approaching the lesion [23,24]. Ranibizumab is also known to have a higher affinity to VEGF [25]. However, the larger size of bevacizumab may guarantee a longer duration of action. In a multicenter, single-blind, prospective study to compare ranibizumab and bevacizumab in 1,208 patients with exudative AMD, the two agents were revealed to have similar treatment effectiveness when intravitreally injected according to the same protocols [26].

In our study, we demonstrated that the two agents led to similar functional and anatomical visual improvement in the 12-month follow-up period when injected as needed after the first intravitreal injection. LogMAR BCVA improved markedly at 1 month after the first injection in both groups, and it was maintained similarly over the follow-up period (Figure 1). The degree of improvement in BCVA at 12 months after intravitreal injections was similar to those reported in previous studies [6-13]. CFT also improved similarly in both groups. CFT decreased significantly at 3 months after injection in both groups, and it maintained this improvement over the follow-up period. Although we could not estimate CFT for all patients at 1 and 2 months post-treatment due to the retrospective nature of this study, the patterns of BCVA improvement strongly suggest that these values would also decrease markedly from baseline CFT. The amount of CFT decrease at 12 months after intravitreal injection was similar to those reported in previous studies, although the absolute values of CFT in the pre- and post-treatment periods were higher than in these studies [6,9,11,12]. The difference is thought to arise from differences in OCT instruments. We used the Spectralis or Cirrus OCT in 39 of 66 eyes, and these modalities are known to estimate retinal thickness more thickly than Stratus OCT [27].

To date, four clinical studies have compared treatment effectiveness after intravitreal injection of ranibizumab and bevacizumab in myopic CNV [14-17]. Gharbiya et al. [14] found that ranibizumab and bevacizumab had similar treatment efficacy in myopic CNV, although the study was limited due to short follow-up. Ruiz-Moreno et al. documented similar visual improvements with the two agents over a 4-year follow-up period in a retrospective study including 92 myopic CNV patients, although the study did not analyze anatomical changes using OCT [17]. Iacono et al. reported that the two intravitreal drugs are effective similarly in the treatment of subfoveal myopic CNV over an 18-month follow-up [16]. In this randomized, prospective study, BCVA (logMAR) improved from 0.59 ± 0.32 to 0.40 ± 0.38, from 0.61 ± 0.28 to 0.44 ± 0.32 at 18 months after treatment in each group, which were similar to our results. However, the mean number of injections was 4.72 ± 2.24 in bevacizumab group and 2.56 ± 1.61 in ranibizumab group, and they insisted that ranibizumab seemed to achieve a slightly greater efficacy than bevacizumab [16]. There were no statistical differences in the number of injections between two drugs in other studies including ours, although 3 studies were retrospective studies [15,17]. The additional intravitreal injection is usually needed to treat a recurring CNV lesion as well as to diminish a naïve lesion, although Iacono et al. [16] did not explain why the patients in bevacizumab group needed more intravitreal injections. The Comparison of Age-related Macular Degeneration Treatment Trial (CATT) study [26] also revealed that intravitreal ranibizumab and bevacizumab injection had a similar effect in exudative AMD when the same protocol was applied and the mean number of injections was similar between two groups (6.9 and 7.7, as needed protocol). Compared with exudative AMD, myopic CNV usually involves a smaller lesion with minimal retinal edema and often accompanies lacquer crack, a rupture of the Bruch membrane. Although no experimental study comparing their pharmacokinetics in high myopia has been reported, these environments would seem to make it easier for anti-VEGF agents to have access to a lesion, ignoring the pharmacologic difference between ranibizumab and bevacizumab. Our results indicated that bevacizumab and ranibizumab have similar effects in the treatment of myopic CNV.

Our study has a few drawbacks. As a retrospective study, it has intrinsic limitations regarding bias control. The patients selected which drugs are injected under sufficient explanation, which would be a selection bias. However, any statistically significant differences were not found in demographic data between two groups. We calculated retinal thickness using several OCT modalities, making comparisons of retinal thickness between patients are less meaningful. However, only one OCT modality was applied to each patient during the follow-up period, which made comparisons of CFT between pre- and post-treatment period reasonable.
Conclusions

In conclusion, we showed that in a retrospective study, ranibizumab and bevacizumab had similar functional and anatomical effectiveness for myopic CNV over a 12-month follow-up period. Given that this conflicts with previous results from Iacono et al. [16], some additional questions remain. A further prospective study controlling explicitly for number of injections across the two groups could yield more conclusive findings.

References

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ: Choroidal neovascularization in young patients. Ophthalmology 1996, 103(8):1241–1244.
2. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M: Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003, 110(7):1297–1305.
3. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Slakter JS, Strong HA, Virgili G, Williams GA: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 1-year results of a prospective pilot study. Br J Ophthalmol 2009, 93(2):150–154.
4. Tran J, Luckat PA, Chung CY, Kim RY: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009, 93(2):150–154.
5. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009, 147(1):94–98.e1.
6. Chan WM, Lai TY, Liu DT, Lam DS: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009, 93(2):150–154.
7. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009, 147(1):94–98.e1.
8. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsukahara M, Gomi F, Tano Y: Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009, 147(1):100–101.e101.
9. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S: Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009, 93(4):448–451.
10. Silva RM, Ruiz-Moreno JM, Nascimento J, Cameiro A, Rosa P, Barrosa A, Carvalheira F, Abreu JR, Cunha-Vaz JG: Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008, 28(8):1117–1123.
11. Vadalà M, Pece A, Cipolla S, Monteleone C, Fasolino G, Casuccio A, Cillino S: Is ranibizumab effective in stopping the loss of vision for choroidal neovascularization in pathological myopia? A long-term follow-up study. Br J Ophthalmol 2010, 94(5):657–661.
12. Wu TT, Kung YH: The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics 2012, 28(2):129–133.
13. Franquelin N, Cachulo ML, Pires J, Fonseca P, Marques I, Figueira J, Silva R: Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica International Journal of Ophthalmology Zeitschrift für Augenheilkunde 2012, 227(1):39–44.
14. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB: Choroidal neovascularization in pathological myopia: intravitreal ranibizumab versus bevacizumab—a randomized controlled trial. Am J Ophthalmol 2010, 149(3):458–464.e451.
15. Lai TY, Luk FO, Lee GK, Lam DS: Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 2012, 26(7):1004–1011.
16. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F: Intravitreal bevacizumab versus ranibizumab for treatment of myopic choroidal neovascularization. Retina 2012, 32(8):1539–1546.
17. Ruiz-Moreno JM, Arias L, Montero JA, Cameiro A, Silva R: Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 2013, 97(11):1447–1450.
18. Aylati MP, Weitzer JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL: Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984, 91(12):1573–1581.
19. Mitchell P, Bandello F, Schmid-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Abreu JR, Cunha-Vaz JG: Ranibizumab for neovascular age-related macular degeneration. The New England journal of medicine 2010, 362(3):301–314.
20. Campochiaro PA, Heier JS, Feiner L, Gray S, Saini N, Rundle AC, Murahashi WY, Rubio RG: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010, 117(6):1102–1112.e1101.
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Intravitreal ranibizumab for neovascular age-related macular degeneration. The New England journal of medicine 2006, 355(14):1419–1431.
22. Mordenti J, Cathriberton RA, Ferrara N, Thomsen K, Berelová L, Licko V, Allen PC, Vokouder CR, Meng YG, Fei DT, Foure KH, Ryan AM: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labelled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicologic pathology 1999, 27(5):536–544.
23. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh R: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007, 114(12):2179–2182.
25. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26(8):859–870.

26. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England journal of medicine 2011, 364(20):1897–1908.

27. Giani A, Cigada M, Choudhry N, Deiro AP, Oldani M, Pellegrini M, Invernizzi A, Duca P, Miller JW, Staurenghi G. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol 2010, 150(6):815–824.

doi:10.1186/1471-2415-14-69

Cite this article as: Cha et al.: Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmology 2014 14:69.